TABLE 3.

Summary of Consensus Recommendations of T&E Regimens for nAMD/PCV

Initiation Phase	Maintenance Phase and Interval Adjustments	Fluid Compartment Considerations
Following nAMD or PCV diagnosis, at least 3 consecutive monthly intravitreal anti-VEGF injections should be given until no disease activity (ie, new hemorrhage or fluid on OCT) is observed	• If no disease activity is observed at FU visits: when using ranibizumab or bevacizumab, inject and extend treatment interval by 2 weeks between visits up to 12 weeks; when using aflibercept, inject and extend treatment interval by 2–4 weeks between visits up to a maximum interval of 16 weeks • If disease activity is observed, inject and shorten the treatment interval by 2–4 weeks, until IRF and/or SRF are not observed, then the treatment interval can be gradually extended	• IRF should always be treated until resolved • For persistent residual SRF despite continuous anti-VEGF injections, subfoveal fluid of ≤200 μm may be tolerated and the treatment interval could be maintained or gradually extended by 2–4 weeks, depending on the anti-VEGF agent, if vision is stable and there are no signs of disease worsening

FU indicates follow-up; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; PCV, polypoidal choroidal vasculopathy; SRF, subretinal fluid; T&E, treat-and-extend; VEGF, vascular endothelial growth factor.